Navigation Links
Targeting disease remission has socio-economic benefits over low disease activity
Date:6/19/2010

Rome, Italy, Saturday 19 June 2010: Achieving disease remission in patients with rheumatoid arthritis (RA) provides superior outcomes across measures of socio-economic importance including work productivity and quality of life according to results presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. These Austrian findings are reported in addition to improvements in measures of physical functioning, when compared with RA patients achieving low disease activity (LDA).

Results from this cross-sectional study of 356 patients showed statistically significant differences (p= < 0.01) between RA patients who had achieved disease remission (REM, defined by the Clinical disease activity Index (CDAI), a composite index including objective and patient derived scores) compared to those who had achieved LDA across several domains including:

  • Effect on work productivity, based on results of the Work Productivity and Activity Impairment (WPAI*) index: impairment while working 11.3% vs. 27.2%, overall activity impairment 18.1% vs. 33.8%, REM vs LDA respectively
  • Impact on quality of life, based on results of the Euro Qol (5D EQ-5D)* index: 0.89 vs. 0.78 and the SF-36 PCS* index: 46.2 vs. 37.8
  • Impact on physical functioning, based on results of the Health Assessment Questionnaire (HAQ*) scores: 0.38 vs. 0.75.

"We know that RA as a chronic disease often has a long term impact on patients' functional ability, affecting not only patients' well-being but also their working lives. The majority of those affected report a loss of productivity at work, and many even have to stop work altogether," said Dr. Helga Radner, Department of Rheumatology, Medical University Vienna, Austria and lead author of the study. "Our study results show that the benefits of achieving clinical remission are worthwhile, especially from a socio-economic point of view, as it decreases the 'burden of disease' not only for patients but also for society on a wider scale. The findings reveal that remission is even superior to an almost perfect disease activity state, namely low disease activity, therefore our major task in treating RA-patients should be its achievement and maintenance"

Interestingly, researchers found that the emotional aspects of the disease activity measures were similarly reported in patients in remission and in low disease activity indicating that once disease activity or symptom levels are reduced to a certain level, emotional discord may stabilise.

Longitudinal analysis over one year showed significant improvements when comparing the two patient populations in the following areas:

  • Quality of life (EQ-5D); 0.89 vs. 0.80 (REM vs. LDA respectively), p < 0.001
  • Percent of overall activity impairment (WPAI) per year; 12.2% vs. 31.0%, p < 0.001
  • Physical disability (HAQ); 0.23 vs. 0.69, p= < 0.001

Significant differences between REM and LDA were not seen in the domain of percentage impairment while working (8.3% vs. 20.0% (REM vs. LDA respectively), p=0.096).

This study of 356 patients registered at the Department of Rheumatology at the Medical University of Vienna involved one cross sectional analysis (at a single time point) of RA patients, with 34 patients achieving REM (CDAI ≤2.8) and 66 patients achieving LDA (2.8≤CDAI<1).

* HAQ is a disability index used by physicians to measure an individual's physical functioning and assesses ability to undertake everyday activities such as dressing, eating and walking, and whether assistance from another person or disability aids is required. A higher score indicates greater disability.

The WPAI questionnaire measures work time missed and work and activity impairment due to a specified health problem during the last 7 days.

The (EQ-5D) is a health-related quality of life scale consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) to which responses can be made at three levels of severity (no problems/some or moderate problems/extreme problems).

The Short Form 36 (SF36) SF-36 is a multi-purpose health survey which yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures.

The Clinical Disease Activity Index allows the assessment of actual disease activity, response to therapy, and achievement of particular states such as remission. The simplicity of the scoring system facilitates patient understanding of the level of their disease activity.


'/>"/>

Contact: Rory Berrie
eularpressoffice@uk.cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Hacker Attacks Targeting Healthcare Organizations Doubled in the 4th Quarter of 2009 According to SecureWorks Data
2. Targeting brain cancer cell metabolism may provide new treatment
3. With White House Jobs Summit This Week KSBH Unveils New TV Ads Targeting Senators on Health Care
4. First live targeting of tumors with RNA-based technology
5. Targeting cancerous vessels
6. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
7. Targeting leukemia cells gene addiction presents new strategy for treatment
8. Americans for Responsible Health Care Launch Radio Ads Targeting Seven Democrats, Warning The People Are Watching...
9. Targeting blood vessels, immune system may offer way to stop infection-caused inflammation
10. Diversinet Extends Reach of Mobile Healthcare Information With New Product Release Targeting Healthcare Organizations
11. Targeting cell pathway may prevent relapse of leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... announced that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... the Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award ...
(Date:4/29/2016)... Toronto, ON (PRWEB) , ... April 29, 2016 ... ... GlutenFreeCoupons.ca and the Canadian Celiac Association (CCA), is pleased to announce the launch ... about gluten-free products, nutritional articles, recipes, and more. The purpose of the ...
(Date:4/29/2016)... NY (PRWEB) , ... April 29, 2016 , ... New York City based oral and ... This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali is ... Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery is ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... enterprise focused entirely on patients with cancer, today announced that Lynne Malestic, RN, ... the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)...   , ... le trimestre, soutenu par une croissance de +42% ... de +16% des ventes aux hôpitaux et cliniques  ... (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur de Cellvizio®, ... chiffre d,affaires pour le premier trimestre clos au ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... its digital health technology platform, which specializes in ... programs into scalable digital products, Zillion enables companies ... and empower consumers to take control of their ... live video conferencing – including one-to-one, group and ...
(Date:4/27/2016)... , April 27, 2016 ... addition of the  "Global Anesthesia Disposables Market ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ,The global anesthesia ... a CAGR of 4.03% during the period ... a major threat to patients, safety. Organizations ...
Breaking Medicine Technology: